Inactivated Vaccines Market Report 2026
Global Outlook – By Type (Viral Vaccine, Bacterial Vaccine), By Method Of Inactivation (Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels) – Market Size, Trends, Strategies, and Forecast to 2030
Inactivated Vaccines Market Overview
• Inactivated Vaccines market size has reached to $6.37 billion in 2025 • Expected to grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.1% • Growth Driver: Rising Prevalence Of Infectious Diseases Boost Inactivated Vaccines Market In Combating Diseases • Market Trend: Innovative Advancements In Inactivated Vaccines By Leading Companies For Disease Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Inactivated Vaccines Market?
Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual. The main types of inactivated vaccines are viral and bacterial vaccines. A viral vaccine is a biological preparation containing weakened or inactivated virus components to stimulate the immune system and provide immunity against the targeted viral infection. These are inactivated by solvent detergent, radiation, pH concentration, heat inactivation and others and are distributed by hospital pharmacies, retail pharmacies and others.
What Is The Inactivated Vaccines Market Size and Share 2026?
The inactivated vaccines market size has grown steadily in recent years. It will grow from $6.37 billion in 2025 to $6.61 billion in 2026 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to rising incidence of infectious diseases, advancements in virology research, government funding for immunization, expansion of healthcare infrastructure, public awareness campaigns for vaccination.What Is The Inactivated Vaccines Market Growth Forecast?
The inactivated vaccines market size is expected to see strong growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing geriatric population, growth in emerging markets healthcare access, technological advancements in vaccine delivery systems, rise in global immunization initiatives, adoption of multi-dose and combination vaccines. Major trends in the forecast period include advancements in vaccine formulation, expansion of cold chain logistics, increasing demand for pediatric vaccines, growth in government immunization programs, development of combination vaccines.
Global Inactivated Vaccines Market Segmentation
1) By Type: Viral Vaccine, Bacterial Vaccine 2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels Subsegments: 1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine 2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague VaccineWhat Is The Driver Of The Inactivated Vaccines Market?
The increasing prevalence of infectious diseases is expected to propel the growth of the inactivated vaccine market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread from person to person, resulting in a wide range of symptoms and health complications. Tuberculosis is one type of infectious disease. Inactivated vaccines use non-living pathogens to stimulate an immune response, effectively preventing diseases such as polio, hepatitis A and influenza. For instance, in November 2023, according to an article published by Centers for Disease Control and Prevention, a US-based national public health agency, the number of tuberculosis patients in the USA has increased from 8,320 in 2022 to 9,615 in 2023 indicating an increase of 1,295 cases. Therefore, the increasing prevalence of infectious diseases is driving the growth of the inactivated vaccine industry.Key Players In The Global Inactivated Vaccines Market
Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Inactivated Vaccines Market Trends and Insights
Major companies operating in the inactivated vaccines market are focusing on expanding product launches and securing regulatory approvals to strengthen their global vaccine portfolios and meet rising immunization needs. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK for use across all age groups in both pre-exposure and post-exposure situations. This launch highlights the company’s ongoing efforts to expand its range of inactivated vaccines and strengthen its global immunization offerings. The move also reflects increasing investments and rising regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and broaden their portfolios, these strategic initiatives are collectively driving significant growth in the inactivated vaccines market, supporting wider protection against infectious diseases.What Are Latest Mergers And Acquisitions In The Inactivated Vaccines Market?
In October 2024, Mankind Pharma Limited, an India-based pharmaceutical company, acquired Bharat Serums & Vaccines Limited (BSV) for an undisclosed amount. With this acquisition, Mankind Pharma aimed to expand into high entry barrier biologics and vaccine manufacturing including capabilities in traditional inactivated vaccines thereby diversifying and upgrading its product portfolio. Bharat Serums & Vaccines is an India-based biopharmaceutical company that develops, manufactures, and markets recombinant biologics, complex injectables, and vaccines, including those using inactivated virus technology.
Regional Insights
North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Inactivated Vaccines Market?
The inactivated vaccines market consists of sales of whole-cell inactivated vaccines, subunit or protein subunit vaccines, conjugate vaccines and toxoid vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Inactivated Vaccines Market Report 2026?
The inactivated vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Inactivated Vaccines Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $6.61 billion |
| Revenue Forecast In 2030 | $8.07 billion |
| Growth Rate | CAGR of 3.9% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Method Of Inactivation, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |